Related Experiment Video

Updated: Aug 17, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.6K

[Anti-inflammatory therapies for cardiovascular diseases: novel evidence, clinical implications, and future

Felice Gragnano1, Paolo Calabrò1, Vincenzo De Sio1

  • 1Dipartimento di Scienze Mediche Traslazionali, Università degli Studi della Campania Luigi Vanvitelli, Napoli - Divisione di Cardiologia, Dipartimento Cardio-Vascolare, AORN Sant'Anna e San Sebastiano, Caserta.

Giornale Italiano Di Cardiologia (2006)
|December 12, 2022
PubMed

Insights

Inflammation drives cardiovascular disease and atherosclerosis. Targeting inflammatory pathways, like interleukin-1/6, offers new hope for managing residual cardiovascular and kidney disease risk.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Nephrology

Background:

  • Inflammation is a key factor in cardiovascular disease (CVD) and atherosclerosis development.
  • Residual inflammatory risk, indicated by high-sensitivity C-reactive protein, persists in patients despite optimal medical therapy for atherosclerotic cardiovascular disease (ASCVD).

Approach:

  • This review examines the intricate relationship between inflammation and ASCVD.
  • It synthesizes current evidence on anti-inflammatory therapies targeting pathways like interleukin (IL)-1 and IL-6.
  • The review also discusses the implications for managing cardiovascular and kidney diseases.

Key Points:

  • Residual inflammatory risk is a significant contributor to cardiovascular events.
  • Therapeutic targeting of the IL-1/IL-6 pathway shows promise for cardiovascular and renal protection.
  • Anti-inflammatory strategies may reduce residual risk in ASCVD patients.

Conclusions:

  • Modulating inflammation represents a promising therapeutic strategy for cardiovascular and kidney diseases.
  • Future clinical practice may incorporate anti-inflammatory treatments to address residual risk in ASCVD.
  • Further research is needed to fully elucidate the role of inflammation in cardiovascular and renal outcomes.

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
26
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
34
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
43
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
65